Sinotherapeutics, Inc.SSE: 688247

Announcement on Provision for Asset Impairment for 2025

Jan 30, 2026 · Issued by Sinotherapeutics, Inc. via Shanghai Stock Exchange

Filed with SSE · Jan 30, 2026

On 6ix: 6ix.com/news/announcement-on-provision-for-asset-impairment-for-2025-23

Announcement on Provision for Asset Impairment for 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Sinotherapeutics, Inc. on 6ix

Earlier from Sinotherapeutics

Summary Announcement on 2025 Restricted Stock Incentive Plan (Revised Draft)Jan 15
Announcement on Voluntary Disclosure of Clinical Trial Applications for Eisaiconazole Sulfate for Injection Approved by China NMPAJan 7
Announcement on Appointment of Senior Management MembersDec 26, 2025
Announcement on Postponement of Investment Projects Financed by Raised FundsDec 13, 2025
Announcement on Voluntary Disclosure of the Renewal and Inclusion of the Company’s Product in the National Medical Insurance CatalogDec 9, 2025

Later from Sinotherapeutics

Announcement on Shareholding Reduction Plan for Shareholders with Over 5% SharesFeb 10
Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Continuation Drug ProcurementFeb 11
Announcement on Preliminary Earnings Estimate for 2025Feb 28
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Vitamin K1 TabletsMar 3
Announcement on Approval by Shanghai Municipal State-owned Assets Supervision and Administration Commission for Abstract of 2025 Restricted Stock Incentive Plan (Revised Draft)Mar 11

All Sinotherapeutics news releases

Follow Sinotherapeutics into a list and get an email when it puts out news.

Follow Sinotherapeutics